FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2090804523> ?p ?o ?g. }

• W2090804523 endingPage "138" @default.
• W2090804523 startingPage "130" @default.
• W2090804523 abstract "Dopexamine has been shown to reduce both mortality and morbidity in major surgery when it is used as part of a protocol to increase oxygen delivery in the perioperative period. A European multicenter study has examined the use of dopexamine in patients undergoing major abdominal surgery, showing a trend toward improved survival and reduced complications in high-risk patients when receiving low-dose dopexamine (0.5 μg · kg(-1) · min(-1)). A reduced oxygen uptake at the anaerobic threshold (AT) has been shown to confer a significant risk of mortality in patients undergoing major abdominal surgery and allows objective identification of a high-risk operative group. In this study, we assessed the effects of low-dose dopexamine on morbidity after major abdominal surgery in patients who were at increased risk by virtue of a reduced AT.Patients undergoing elective major colorectal or urological surgery who had an AT of <11 mL · kg(-1) · min(-1) or an AT of 11 to 14 mL · kg(-1) · min(-1) with a history of ischemic heart disease were recruited. Before surgery, a radial arterial cannula was placed and attached to an Edwards Lifesciences FloTrac/Vigileo system for measuring cardiac output. Patients were given a 250-mL bolus of Voluven (6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride) until the stroke volume no longer increased by 10%, then received either dopexamine (0.5 μg · kg(-1) · min(-1)) or saline 0.9% for 24 hours. During surgery, fluid boluses of Voluven were given if the stroke volume variation was >10%. No crystalloid was given during surgery. A standardized postoperative fluid regime with Hartmann solution was prescribed at 1.5 mL · kg(-1) · h(-1) for 24 hours. The primary outcome measure was postoperative morbidity measured by the Postoperative Morbidity Survey.One hundred twenty-four patients were recruited over a 23-month period. The incidence of morbidity as measured by the Postoperative Morbidity Survey on day 5 was 55% in the control group versus 47% in the dopexamine group (P = 0.14). There was no significant reduction in morbidity on any measured postoperative day. Complication rates, mortality, and hospital length of stay were similar between the 2 groups; however, administration of dopexamine was associated with earlier return of tolerating an enteral diet.With the effective use of goal-directed fluid therapy in elective surgical patients, the routine use of dopexamine does not confer an additional clinical benefit." @default.
• W2090804523 created "2016-06-24" @default.
• W2090804523 creator A5015108424 @default.
• W2090804523 creator A5027404682 @default.
• W2090804523 creator A5060885527 @default.
• W2090804523 date "2011-01-01" @default.
• W2090804523 modified "2023-09-23" @default.
• W2090804523 title "Dopexamine Has No Additional Benefit in High-Risk Patients Receiving Goal-Directed Fluid Therapy Undergoing Major Abdominal Surgery" @default.
• W2090804523 cites W1590758521 @default.
• W2090804523 cites W170959490 @default.
• W2090804523 cites W1964337533 @default.
• W2090804523 cites W1979669873 @default.
• W2090804523 cites W1987191192 @default.
• W2090804523 cites W1987519900 @default.
• W2090804523 cites W1992332433 @default.
• W2090804523 cites W2000746267 @default.
• W2090804523 cites W2008160010 @default.
• W2090804523 cites W2014630392 @default.
• W2090804523 cites W2018308183 @default.
• W2090804523 cites W2024417195 @default.
• W2090804523 cites W2036944390 @default.
• W2090804523 cites W2040491697 @default.
• W2090804523 cites W2041084473 @default.
• W2090804523 cites W2046678081 @default.
• W2090804523 cites W2046922485 @default.
• W2090804523 cites W2050636348 @default.
• W2090804523 cites W2062600392 @default.
• W2090804523 cites W2073141423 @default.
• W2090804523 cites W2085493796 @default.
• W2090804523 cites W2102551629 @default.
• W2090804523 cites W2104629752 @default.
• W2090804523 cites W2107917605 @default.
• W2090804523 cites W2110843198 @default.
• W2090804523 cites W2114152921 @default.
• W2090804523 cites W2129438007 @default.
• W2090804523 cites W2130730383 @default.
• W2090804523 cites W2140338960 @default.
• W2090804523 cites W2146323909 @default.
• W2090804523 cites W2147439751 @default.
• W2090804523 cites W2152990840 @default.
• W2090804523 cites W2156967952 @default.
• W2090804523 cites W2167438595 @default.
• W2090804523 cites W2169250915 @default.
• W2090804523 cites W2170665477 @default.
• W2090804523 cites W2170890039 @default.
• W2090804523 cites W2172056944 @default.
• W2090804523 cites W2776640398 @default.
• W2090804523 cites W4245454113 @default.
• W2090804523 cites W4248793270 @default.
• W2090804523 doi "https://doi.org/10.1213/ane.0b013e3181fcea71" @default.
• W2090804523 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21048092" @default.
• W2090804523 hasPublicationYear "2011" @default.
• W2090804523 type Work @default.
• W2090804523 sameAs 2090804523 @default.
• W2090804523 citedByCount "31" @default.
• W2090804523 countsByYear W20908045232012 @default.
• W2090804523 countsByYear W20908045232013 @default.
• W2090804523 countsByYear W20908045232014 @default.
• W2090804523 countsByYear W20908045232015 @default.
• W2090804523 countsByYear W20908045232016 @default.
• W2090804523 countsByYear W20908045232017 @default.
• W2090804523 countsByYear W20908045232019 @default.
• W2090804523 countsByYear W20908045232020 @default.
• W2090804523 crossrefType "journal-article" @default.
• W2090804523 hasAuthorship W2090804523A5015108424 @default.
• W2090804523 hasAuthorship W2090804523A5027404682 @default.
• W2090804523 hasAuthorship W2090804523A5060885527 @default.
• W2090804523 hasBestOaLocation W20908045231 @default.
• W2090804523 hasConcept C126322002 @default.
• W2090804523 hasConcept C141071460 @default.
• W2090804523 hasConcept C2777953023 @default.
• W2090804523 hasConcept C2779412105 @default.
• W2090804523 hasConcept C2780120127 @default.
• W2090804523 hasConcept C31174226 @default.
• W2090804523 hasConcept C42219234 @default.
• W2090804523 hasConcept C43376680 @default.
• W2090804523 hasConcept C71924100 @default.
• W2090804523 hasConcept C80461066 @default.
• W2090804523 hasConcept C84393581 @default.
• W2090804523 hasConceptScore W2090804523C126322002 @default.
• W2090804523 hasConceptScore W2090804523C141071460 @default.
• W2090804523 hasConceptScore W2090804523C2777953023 @default.
• W2090804523 hasConceptScore W2090804523C2779412105 @default.
• W2090804523 hasConceptScore W2090804523C2780120127 @default.
• W2090804523 hasConceptScore W2090804523C31174226 @default.
• W2090804523 hasConceptScore W2090804523C42219234 @default.
• W2090804523 hasConceptScore W2090804523C43376680 @default.
• W2090804523 hasConceptScore W2090804523C71924100 @default.
• W2090804523 hasConceptScore W2090804523C80461066 @default.
• W2090804523 hasConceptScore W2090804523C84393581 @default.
• W2090804523 hasIssue "1" @default.
• W2090804523 hasLocation W20908045231 @default.
• W2090804523 hasLocation W20908045232 @default.
• W2090804523 hasOpenAccess W2090804523 @default.
• W2090804523 hasPrimaryLocation W20908045231 @default.
• W2090804523 hasRelatedWork W1978251693 @default.
• W2090804523 hasRelatedWork W2002626821 @default.
• W2090804523 hasRelatedWork W2045100276 @default.

• next